Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
October 13, 2022 06:00 ET
|
Editas Medicine, Inc.
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated...
Editas Medicine to Participate in Upcoming Investor Conferences
September 01, 2022 06:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
August 03, 2022 06:29 ET
|
Editas Medicine, Inc.
Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease;...
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
July 27, 2022 06:30 ET
|
Editas Medicine, Inc.
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a...
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
July 26, 2022 06:26 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
July 20, 2022 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly...
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
July 18, 2022 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the...
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
June 07, 2022 07:00 ET
|
Editas Medicine, Inc.
TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery...
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
June 06, 2022 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
May 18, 2022 06:45 ET
|
Editas Medicine, Inc.
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo...